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Background: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs,
requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy
to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP)
conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage
repair.
Methods: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any
cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory
expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered
scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a
tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity
studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied
1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected
organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC).
Results: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect
indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation,
macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the
implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they
were of spontaneous murine origin.
Conclusions: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety
studies of ATMPs.
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Novel therapies using cell-based ATMPs require special
safety testing strategies. These cell-based ATMPs can
be classified as somatic cell therapy medicinal products
(sCTMPs), tissue engineered products (TEPs), or combined
ATMPs. Product development and testing must be in com-
pliance with regulatory requirements, and the compiled
data need to be reviewed by regulatory authorities such as
the European Medicines Agency (EMA) in the European
Union (EU) or the Food and Drug Administration (FDA) in
the United States of America. For non-clinical develop-
ment, conventional efficacy and safety testing strategies as
established for small molecules or biopharmaceuticals
have been shown to be inapplicable and unsuitable for
ATMPs. Nevertheless, ATMPs must fulfill other strict test-
ing requirements including the acquisition of safety data for
authorization by regulatory authorities for clinical trial or
marketing approval [1,2]. In the EU, these requirements are
laid down by the European Commission in Directive 2009/
120/EC, amending the overarching medicinal product
Directive 2001/83/EC by implementing specific demands
for ATMPs. This includes unintended biodistribution of
the implanted cells, referring to their distribution or
migratory potential, as well as their tumorigenic risk,
referring to their potential to transform and generate
tumors, and their potential immunotoxicity or immuno-
genicity in the patient [3].
In this work, a strategy was developed and applied to
assess the biodistribution and tumorigenicity of a TEP for
cartilage repair, human chondrocyte spheroids (co.don
chondrosphere®) referred to here as huChon spheroids.
These spheroids are a solid cell complex with a self-
synthesized extracellular matrix that is formed by self-
aggregation in appropriate culture conditions, and the
spheroids are used for the treatment of focal lesions in
articular knee cartilage [4,5]. Studies of efficacy and proof
of concept including aspects of basic safety of the huChon
spheroids were done under GLP conditions in an ortho-
topic sheep animal model to mimic the human situation
[6]. In the present comprehensive two-stage safety study,
an immunodeficient inbred mouse strain was chosen
to evaluate subcutaneously transplanted huChon spher-
oids for undesirable biodistribution into circumjacent
mouse tissues and selected organs as well as for signs
of tumorigenicity.
The whole study, consisting of biodistribution and
tumorigenicity components, was performed under GLP
conditions that require detailed standard operating pro-
cedures (SOPs) for each step. Manipulation of the test
item, e.g. by labeling with fluorescent dyes, quantum
dots, ferromagnetic particles or by introduction of
reporter genes such as luciferase, was regarded to be
unsuitable because this may result in altered functional
and safety properties of the test item [7–10]. The testitem must reflect the essential features of the final
ATMP produced under good manufacturing practice
(GMP) or should ideally even be identical to this. Thus,
methods requiring in-vivo labeling of huChon were ex-
cluded. In order to achieve regulatory feedback prior to
initiating a time- and cost-intensive GLP-study, the pro-
ject concept included several scientific advice meetings
with the Paul-Ehrlich-Institute (PEI), the responsible
regulatory authority for ATMPs in Germany. The GLP
study design was prospective, randomized, actively con-
trolled and performed under blinded label for the obser-
ver analyses using test items derived from the GMP
manufacturing unit.
Methods
Study plan
Regulatory affairs
Equipment, materials, and methods including mouse
breeding, the animal model, all assays and validation of
each step were used or performed according to detailed
institutional SOPs in accordance with the principles of
GLP as described under § 19a, German Chemical Law and
in the GLP handbooks of the WHO and OECD [11,12].
All study-relevant SOPs are available on request.
The study plan was conducted in accordance with the
recommendations of the Committee for Advanced Ther-
apies (CAT), the scientific expert committee for ATMPs
at the EMA [13], and the reflection paper on in vitro
cultured chondrocyte-containing products for knee car-
tilage repair [6]. The study plan, documented in the flow
charts (Figs. 1 and 2) and agreed upon by the respon-
sible national regulatory authority, the PEI, was realized
with the elaborated SOPs. All critical parameters of this
GLP study, i.e. NSG mouse model, subcutaneous vs.
orthotopic application route, dose, number of animals
and patients, duration of follow-up in the biodistribution
and tumorigenicity studies and general methodology of
recovery of human cells were defined after discussion
with the authority. This study was performed at the
Fraunhofer Institute for Cell Therapy and Immunology
(IZI) Leipzig as a legal GLP test facility under the study
code Fh-IZI-04-huChon (COD16/TS09). Any deviation
from the SOPs was documented in a deviation report
and approved by the study director and the head of the
test facility management.
Mouse model
All mice procedures were approved by the local ethics com-
mittee for experimental animal studies (Landesdirektion
Sachsen, A06/11) and thus were in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles
River, Margate, UK) are recommended for examining
biodistribution of human xenografts [14]. Female NSG
Fig. 1 (See legend on next page.)
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Fig. 1 Flow chart of the biodistribution study under GLP conditions. The methods and decision points shown in continuous lines and rectangles
were performed within the presented biodistribution study. Steps in dashed lines were prospectively planned but were not necessary to perform.
Methods shown as a rhombus may have at least two outcomes. The Roman numerals are used in order to match each step in this flow chart
with the corresponding explanation in the “Results” section. aHuChon spheroids from five different patients were implanted, eight mice were
treated per patient, each treated with 1 spheroid, and thus 40 mice were analyzed. bIn mouse MB1 (1/40) the huChon spheroid could not clearly
be identified macroscopically at the implantation site. Thus, complete qPCR analyses of organs were performed. c17 samples could not be
evaluated (n.e.) by IHC due to technical reasons. The further analyses of these mice are shown in an additional flow chart in the Supplement
(Additional file 3: Figure S3). In case of detection of human cells or DNA within the five selected organ/tissue types (lungs, liver, left and right
kidney, spleen, and pooled local lymph nodes) the study would have to be repeated with a second cohort of 40 mice with a follow up of 61 ±
1 days. If biodistribution had been confirmed, the upstream tumorigenicity study (see below) would be performed with particular attention to
the afflicted organs
Zscharnack et al. Journal of Translational Medicine  (2015) 13:160 Page 4 of 17mice, 7–9 weeks of age, were housed under special
pathogen-free conditions in individually ventilated cages
and received food and water ad libitum.
Test and reference items
Chondrocyte 3D spheroids (Fig. 3a) produced in vitro from
human articular chondrocytes (co.don chondrosphere®,
co.don® AG, Teltow, Germany), referred to here as huChon
spheroid, were examined as an ATMP. Chondrocytes were
taken exclusively from female patients who underwent the
initial surgery for the autologous chondrocyte transplant-
ation procedure. The cells were cultivated as monolayers
for 21–33 days. The spheroids with an average diameter of
500 ± 70 μm were manufactured by co.don® as described
previously [15]. Briefly, huChon spheroids were prepared
with 2 × 105 chondrocytes from passage 2 or 3 and cultured
for an additional 21–31 days. The production-relevant
quality and safety tests were performed under the supervi-
sion and on the premises of co.don similar to the proced-
ure required for GMP. The huChon spheroids complying
with the requirements of the quality control program were
transferred to the GLP test facility. The mouse embry-
onic fibroblast cell line NIH/3T3 and the human colo-
rectal adenocarcinoma cell line Caco-2 (both ATCC; LGC
Standards GmbH, Wesel, Germany) were used for
references of the tumorigenicity study. Aggregation of
NIH/3T3 was accomplished by centrifugation of 0.2 × 106
cells at 780 × g for 5 min and by cultivation of these pellets
for 24 h. Spheroid analogues from Caco-2 cells were pro-
duced according to the co.don chondrosphere® protocol.
Implantation of spheroids
The spheroids or spheroid analogues were implanted
subcutaneously into the back of the mice 1 cm caudally
from the occipital pole under anesthesia with 65 mg/kg
ketamine (Bela-Pharm, Vechta, Germany) and 13 mg/kg
xylazine (Bayer HealthCare, Leverkusen, Germany). A
0.5 cm skin incision was made and the spheroids were
inserted by means of a micro-spatula (Fig. 3b). The wound
edges were tattooed with a sterile 26-gauge needle and
black tattoo paste (Peter Hennes, Haan, Germany) for
locating the implantation site.Biodistribution
The complete process of the prospective biodistribution
study, including multi-step analysis and important deci-
sion points, is illustrated in a detailed flow chart (Fig. 1).
HuChon spheroids of five female patients were analyzed.
One huChon spheroid was implanted per mouse. Eight
mice were treated per patient, thus 40 mice were ana-
lyzed. After implantation of huChon spheroids, the mice
were inspected daily, weighed and palpated weekly, and
their health was scored using a system modified ac-
cording to te Velde et al. [16], and the German Society of
Laboratory Animals (score 0: normal; score 1: shaggy fur;
score 2: withdrawn behavior, eating less, humped-up pos-
ture; score 3: apathetic behavior, weight loss of > 20 %).
The break-off criteria were: health score 3 or health score
2 combined with a tumor or an open wound. After sacri-
fice, which was performed 31 ± 1 days after implantation,
the area surrounding the implantation site was judged by
macroscopic inspection and the whole mouse body was
palpated. Subsequently, a 3.5 × 5 cm skin area was
explanted from the back, spread on a petri dish (Fig. 3c)
and the huChon spheroid was observed macroscopic-
ally and microscopically using an inverse microscope
(Axiovert, Zeiss, Oberkochem, Germany). Using a three-
part biopsy punch developed in house (Fig. 3d), a 4-mm
diameter skin disc and two circumjacent ring punches,
10-20 mm diameter (Fig. 3e), were obtained. The 4-mm
disc (Fig. 3f), with the spheroid in its center and frozen at
−80 ± 5 °C in cryomolds with Tissue-Tek® (Jung, Nussloch,
Germany), was used for IHC of potentially migrated hu-
man cells. The circumjacent 10-mm ring within a radius
of 2-5 mm from the implant was examined for the pres-
ence of human DNA by qPCR. The circumjacent 20-mm
ring within the radius of 5-10 mm distance from the
implant was cryopreserved in cryotubes at −80 ± 5 °C
for optional qPCR analysis if the 10-mm ring was
tested positive for human DNA. Further, five different
organs—lungs, liver, the two kidneys, spleen, and local
lymph nodes (pooled from each mouse)—were isolated,
weighed and one third of each tissue was frozen in Tissue-
Tek® at −80 ± 5 °C for optional IHC. The remaining organ
portions were frozen at −20 ± 5 °C for optional qPCR.
Fig. 2 Flow chart of the tumorigenicity study under GLP conditions. The methods and decisions shown in continuous lines and rectangles were
performed within the tumorigenicity study presented here. The rectangle in dashed lines refers to a potential outcome of huChon group that did
not occur. Methods shown as a rhombus may have two outcomes. The Roman numerals are used in order to match each step in this flow chart
with the corresponding explanation in the “Results” section. a(within the topmost rectangle) huChon spheroids from five different patients were
implanted, eight mice were treated per patient, 5 spheroids per mouse were implanted and thus 40 mice were analyzed. In two mice of the
huChon group a benign tumor was detected. However, both tumors were anti-HLA-ABC negative suggesting that the tumors were spontaneous
murine and not derived from human cells. Thus, there was no evidence for increased tumorigenicity after implantation of the huChon spheroids
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Fig. 3 huChon spheroids, their implantation and the isolation of skin areas in the biodistribution study using a three-part punch. HuChon spheroids in
a drop of a syringe ready for implantation after GMP manufacturing (a). Subcutaneous implantation of a single huChon spheroid (arrow)
by a micro-spatula into the back of the NSG mouse, 1 cm caudally from the occipital pole (b). The spatula had marks every 0.5 cm to ensure correct
implantation. The isolated back skin with the two tattoo points from the former wound edges as orientation were spreaded for punching in a Petri
dish (c). Three-part punch, developed for this study (d). Closer look with the labeling of the three skin areas, the inner 4-mm disc has been punched
out (e). Representative example of such a punched out 4-mm disc with the spheroid (f, arrow). Scale bars: c: 10 mm, e: 4 mm, f: 1 mm
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human cells/DNA within the analyzed organ types, the
study would have to be repeated with a second cohort of
40 mice, with a follow up of 61 ± 1 days. If biodistribu-
tion had been confirmed, an upstream tumorigenicity
study would be performed with particular attention to
the affected tissues or organs.
Tumorigenicity
The complete process of the prospective study is illus-
trated in a detailed flow chart (Fig. 2). HuChon spheroids
of five additional female patients were analyzed. Five
huChon spheroids were implanted per mouse. Eight mice
were treated per patient, thus 40 mice were analyzed. For
reference group 1, 20 Caco-2 spheroids, each containing
0.5 × 106 cells, were implanted per mouse (n = 11) to en-
sure tumor formation [17]. As reference group 2, pro-
spectively planned as a negative reference, five spheroid
analogues with a total of 1 × 106 NIH/3T3 cells were im-
planted per mouse (n = 8). The planned husbandry period
was 180 ± 5 days. After sacrifice, the mice were palpated
and macroscopically inspected for tumors. Tumor sizewas measured with a caliper to calculate volume. Mice
were dissected and any tumors or abnormalities at the
implantation site or organs were prepared and frozen in
cryomolds with Tissue-Tek® at −80 ± 5 °C. The selected
organs were isolated, weighed and frozen as described for
biodistribution. Serial sections of the tumors and suspi-
cious areas were analyzed by HE and HLA-ABC staining.
DNA extraction
To prevent any contamination with human female cells
or DNA, all experiments were performed by male staff
only. The complete 10-mm skin ring and the samples of
isolated organs were weighed, mechanically minced with
scalpels and lysed with 0.5 μg proteinase K (Promega,
Mannheim, Germany) per mg tissue under continuous
shaking at 56 °C for 90 min. The DNA was automatically ex-
tracted using the Maxwell® 16 Mouse Tail DNA Purification
Kit at the Maxwell 16 IVD Instrument (both Promega) in
the “standard elution volume” mode. First, the extrac-
tion process was validated. Intra-assay variation, i.e. the
coefficient of variation (CV) between three different
DNA extractions from a single skin lysate in the same
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repeated on three different days. The overall intra-assay
variability was 2.85 ± 0.8 %. Inter-assay variation was
examined between the same three runs. The CV value was
0.94 ± 2.1 % (Table 1).
To test for possible saturation of the DNA extraction
when increasing the amount of skin lysate per cartridge,
DNA was prepared from 5 mg up to 69 mg skin in 3 mg
steps. Within this range, the amount of extracted DNA
per cartridge increased linearly. Thus, per cartridge up
to 50 mg tissue sample were used.
If two or more cartridges were used for a punched skin
ring or tissue sample the extracted DNA was pooled. The
volume of each DNA was determined for calculation of
possible number of PCR reactions.
Triplex qPCR
Triplex qPCR was performed using the Plexor® HY Assay
(Promega), which offers a combination of simultaneous
quantification of human autosomal and Y-chromosomal
DNA, with a LightCycler® 480 instrument (Roche Diagnostics,
Mannheim, Germany). Multi-copy sequences on chromo-
some 17 and on the Y chromosome were targeted in order
to detect human autosomal DNA or male DNA, re-
spectively. Because implantation of the huChon spheroids
from female donors and the downstream qPCR analysis
were exclusively done by male lab personnel, the gender-
specific primers allowed discrimination of donor DNA
from DNA contaminated by lab personnel. A third novel
DNA sequence was included in the primer mix as an in-
ternal PCR control (IPC). In each run, a negative control
without template and a calibration curve consisting of
seven log5 dilution steps created from the Plexor
® HY male
gDNA standard calibrator were included in triplicate.
Each PCR reaction contained 10 μl Plexor® HY 2x mas-
ter mix, 1 μl Plexor® HY 20X primer/IPC mix and 9 μlTable 1 Validation of the DNA extraction process
A) DNA concentrations and the resulting intra-assay variation betwee
same run. “Eluate 1–3” are different extractions using three differen
in triplicate (assay 1–3 at three different days)
DNA concentration [ng/μl]
Eluate 1 Eluate 2 Eluate 3
Assay 1 219.0 231.6 223.8
Assay 2 219.7 234.7 219.8
Assay 3 219.9 225.8 217.7
Mean
SD
B) Mean DNA concentrations of the validation runs at three different
DNA concentration [ng/μl]
Assay 1 Assay 2 Assay 3
224.8 224.7 221.1sample DNA template. From each skin ring or tissue
sample, at least 1/3 of the total extracted DNA volume
was used for qPCR. That means 1/3 of DNA volume di-
vided by 9 determined the minimal number of PCR reac-
tions per skin ring or tissue sample. The minimal number
of qPCR reactions per skin sample was 19. The maximum
number was 102 reactions. Data were analyzed using the
Plexor® analysis software (Promega). Assignment of refer-
ence standard reactions for the calibration curve or nega-
tive control and adjustment of expected target melt
temperatures were done according to the Plexor® HY
protocol. Three channels were estimated for each qPCR
reaction: “IPC”, “human autosomal” and “male”. “IPC”
must be positive, otherwise the analysis for this reaction
was stopped. A reaction was considered positive for the
“human autosomal” and/or “male” channel if extrapolated
by the Plexor® analysis software.
Determination of detection limits in DNA extraction
combined with qPCR
In order to evaluate the sensitivity and specificity for hu-
man female DNA, decreasing numbers of human chon-
drocytes were transferred into tubes containing up to
50 mg fresh mechanically-minced sterile murine skin to
undergo further proteinase K lysis. DNA was extracted
and used completely for qPCR. Reference standard reac-
tions were performed in parallel. The analysis was carried
out in triplicate on three consecutive days. At the end, the
percentage of positive qPCR results of one murine skin
sample substituted with a decreasing number of human
female chondrocytes was calculated for the channels
“human autosomal” and “male” to determine sensitivity
and specificity, i.e. the contamination rate. Reactions
positive for both channels were considered to have been
contaminated by the male staff and were not included in
calculations.n three different DNA extractions from a single skin lysate in the
t Maxwell cartridges within one run. The values were determined
Intra-assay variability [%]
Mean SD
224.8 6.36 2.83
224.7 8.63 3.84
221.1 4.19 1.89
2.85
0.8
days (assay 1–3) and resulting inter-assay variation.
Inter-assay variability [%]
Mean SD
223.5 2.10 0.94
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qPCRs/cell number). All qPCR analyses were positive using
100 or more cells. In a second series 5, 10, 20, 50 or 100
cells (n = 60 qPCRs/cell number) were added. All qPCR
analyses were 100 % positive using 20 or more cells. In a
third series 1, 2, 3, 4, 5 or 10 cells (n = 120 qPCRs/cell
number) were added. Human autosomal DNA was de-
tected in 98.3 ± 1.2 % with five cells (Fig. 4l). For less than
five cells, detection was not reliable and reproducible.Fig. 4 Biodistribution study: Detection of the huChon spheroids within the
subcutis; the figures show a representative example of a normally shaped h
spheroid was macroscopically visible as faint yellowish stain (a, arrow). Light m
(c, red-brown staining). Haematoxylin was used as a counterstain. The fragm
(d, arrow). A Light microscopic view of a fragmented spheroid is show
shown in (f). The arrows indicate the two fragments. As positive control, HLA
was used (g). IgG2a isotype control of this specimen is shown in (H).
500 μm (a, d). A 3D reconstruction of a representative huChon sphero
were registered onto another to realign adjacent slices. Afterwards, eac
Gaussian filter was used to smooth the data for visualization and afterwards
algorithm implemented in Mathematica 9.0.1. Depending on the section leve
The white arrows in (i) and (j) indicate “bulges” of the spheroid. Scale bars ind
extraction and the Plexor® HY PCR (l). The sensitivity and reproducibility of the
numbers of human chondrocytes to 50 mg mouse skin tissue. Five cells repre
reproducibly positiveThus, 5 cells at minimum were required within one DNA
extraction and qPCR process to detect human autosomal
DNA reproducibly.
Furthermore, the percentages of positive qPCR results
for one channel were calculated. The threshold percentage
for a DNA sample to be considered positive for “human
autosomal” was calculated as [100−2x ratio of (number of
negative reactions/number of all reactions)], therefore
adjusting the threshold downwards (unadjusted values).mouse skin. Detection of implanted huChon spheroids within mouse
uChon spheroid (a–c) and a fragmented spheroid (d–f). The huChon
icroscopic view of the spheroid (b). HLA-ABC staining of this specimen
ented huChon spheroid is only very weakly visible macroscopically
n in (e). BV: Blood vessel. HLA-ABC staining of a fragmented spheroid is
-ABC staining of a single huChon spheroid without mouse tissue
Scale bars indicate 100 μm (g, h), 200 μm (b, c, e, and f) or
id from nine serial sections was performed (i). The digitized images
h image was binarized to a separate background. An anisotropic
the surface of the volume was reconstructed using the ListContourPlot3D
l (grey arrows), this huChon spheroid appeared fragmented (j) or not (k).
icate 100 μm. The determination of the lower detection limit for DNA
DNA extraction and qPCR were tested in parallel by adding increasing
sented the lowest cell number at which almost all of the reactions were
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120 reactions, the percentage of positive qPCR results was
96.6 %. That means a mouse tissue was considered posi-
tive for at least five human cells when 96.6 % of the reac-
tions were positive for “human autosomal”.
The threshold percentage for a DNA to be contami-
nated overly with male DNA to be undoubtedly identified
as female was calculated as [2x ratio (number of positive
reactions in channel “male”/all reactions)]. It was 30 %, as
there were 18 positive reactions in channel “male” within
120 reactions. If less than 30 % of the reactions of a sam-
ple were also negative for the “male” qPCR channel, fe-
male DNA was present. Male DNA was detected in 3.1 ±
1.2 % of all validation qPCR analyses, whereby 93.5 ± 5.1
% of these reactions correlated with human DNA and can
thus be explained by a contamination of male staff. That
means 6.5 ± 5.1 % of the qPCR analyses positive for male
DNA were false positive.qPCR statistics
For each murine tissue sample, we determined whether
it contained a certain number of human cells. PCR sta-
tistics involved the application of a two-sided confidence
interval to the calculated percentages of positive qPCRs
results per DNA sample and channel, extending the cal-
culated value both upwards and downwards by a range
of uncertainty in which the value might also be found.
Because in murine male tissue samples human female
chondrocyte DNA should be detected which was ex-
tracted by male staff, the criteria for evaluating the chan-
nels “human autosomal” and “male” were made stricter by
adjusting the channel “human autosomal” values upwards
and the channel “male” values downwards for the uncer-
tainty. These adjusted percentages were compared with
channel-dependent threshold percentages resulting from
validation experiments. Reaching or exceeding the chan-
nel “human autosomal” threshold allowed this DNA sam-
ple to be judged positive for a minimum of human cells
during DNA extraction which was determined during
qPCR validation. If the channel “human autosomal” was
positive but simultaneously the threshold of the “male”
channel was not reached (undershooting), the cells were
additionally categorized as female. If the channel “male”
threshold was exceeded, the DNA was considered to be
overly contaminated with male DNA derived from lab
personnel.HE staining and immunohistochemistry
For HE staining, the 10 μm cryosections were fixed with
10 % paraformaldehyde for 15 min, washed twice with
deionized water and stained with filtered hematoxylin
solution (Morphisto, Frankfurt, Germany) for 10 min.
After washing with tap water for 15 min and a shortwashing step with distilled water, the sections were stained
with 1 % eosin (Morphisto) for 3 min.
In order to detect potentially migrated human cells
within the 4-mm skin disc with high sensitivity and speci-
ficity by immunohistochemistry, the staining protocol was
optimized. The particular challenge was to achieve specific
staining of the spheroids, fragments or single chondro-
cytes without any background staining of murine tissue.
The epidermis often shows non-specific staining due to its
expression of endogenous peroxidase [18]. Several block-
ing steps including inhibition of the endogenous peroxid-
ase, incubation of the tissue sections with human serum
before incubation with the primary anti-human antibody,
and adding species-specific serum to the secondary anti-
body resulted in distinguishable staining in pilot batches
(Additional file 1: Figure S1).
At the end, the following optimized staining protocol
was applied under GLP conditions: The complete 4-mm
disc was cut vertical to the epidermis into serial 10 μm
cryosections. To reduce the sample size, only every second
section was labeled with a serial number and immunohis-
tochemically stained. Prior to the staining, the sections
were fixed with acetone for 10 min, incubated with 0.3 %
H2O2 in PBS for 30 min to block endogenous peroxidase
activity, washed twice with PBS and incubated with 1 %
human AB serum (Sigma-Aldrich, Deisenhofen, Germany)
for 15 min. The serum was removed and the sections were
incubated with the primary anti-HLA-ABC mouse mono-
clonal antibody (clone W6/32) or alternatively with an
IgG2a isotype control antibody (both DakoCytomation,
Hamburg, Germany) for 90 min at room temperature.
Then, the sections were washed three times and incubated
with horseradish peroxidase-conjugated goat anti-mouse
IgG (Dianova, Hamburg Germany), supplemented with
1.5 % goat serum, for 45 min at room temperature. After
three washing steps the sections were developed with
3–amino–9–ethyl–carbazol (AEC) as substrate (Sigma-
Aldrich). The nuclei were counterstained with Mayer’s
hematoxylin (DakoCytomation). Spheroid cryoslides of
the relevant patients were used in parallel as positive
controls.
The slices were assessed blindly by two independent ex-
perts. The primary aim was to reveal direct signs of active
migration such as a corona-forming spread of chondro-
cytes starting from the implanted spheroid. The secondary
aim was to find indirect signs of migration resulting from
migrated cells. This included the occurrence of tumors,
infiltration of neutrophilic granulocytes, and induction of
necrosis or apoptosis seen as cell shrinkage, formation of
apoptotic bodies or pyknotic chromatin [19].
After optimization and validation of immunohistochem-
istry, a GLP-compliant SOP was generated. Reproducibility
of the method was tested by validation stainings carried
out on three consecutive days.
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Karyotyping was not performed under GLP conditions.
Chromosomes were prepared from NIH/3T3 cells using
standard cytogenetic techniques [20]. For karyotyping, we
analyzed metaphases of cultured cells using GTG-banding
[21] and the SKY-technique according to the manufac-
turer’s instructions at chromosome spreads. Twenty-five
metaphases (12 GTG- banding, 13 SKY) were analyzed
two times: within the first and within the 14th passage (at
the time of implantation). Additionally, small pieces of
NIH/3T3-derived mouse tumors were transferred to cul-
ture flasks. The resulting outgrown cells were karyotyped
as well.
Statistics
Results for all variables are presented as mean ± standard
deviation (SD). Patient group differences (8 mice per pa-
tient group) in the mouse body and organ weights as
well as their changes versus baseline were investigated
by analysis of variance (ANOVA). Two-group compari-
sons of distributions were performed by t-test. For all ana-
lyses, p-values <0.05 were regarded as significant. With
exception of Tukey’s post-hoc test, which addresses multi-
plicity of all pairwise comparisons between subjects in
ANOVA, no correction in terms of multiple testing was
applied.
Regarding the evaluation of 40 animal organs by qPCR
out of 102 organs (corresponding to 7 out of 17 mice,
see Additional file 1: Figure S1) we followed ISO 2859-I,
Tables I and II. Regarding the evaluation of 40 animal or-
gans by qPCR out of 102 organs (corresponding to 7 out of
17 mice, see Additional file 1: Figure S1) we followed ISO
2859-I, Tables I and II. The operational characteristic used
in ISO 2859-I could also be estimated by applying a for-
mula for binomial distribution calculating probabilities 1-α
(typically =95 %) or β (typically 20 (10 %) in dependence on
underlying probability of a positive event p, observed events
(=0) and sample size N e. g. by using MS Excel (Formula
BINOM.VERT(0 [=observed events]; N [=sample size];
p [=underlying probability]; 0 [cumulative = no]).
Results
Test strategy
The complete established two-staged test strategy is sum-
marized in two flow charts (Figs. 1 and 2), which provide
an overview for the whole, multi-step process with im-
portant decision points. The application of several analysis
methods (Fig. 1, methods I–VII for biodistribution study
and Fig. 2, methods I–IX for tumorigenicity) ensured a
high degree of significance and level of security for the
final evaluation of the results. Further, the use of a multi-
level procedure, in which more in-depth analyses are trig-
gered by a positive result in the previous analysis, allows
for cost efficiency.Biodistribution study
The flow chart in Fig. 1 summarizes both the prospect-
ive planned biodistribution study as well as the obtained
results.
Normal health state and weight progression with no
abnormalities
After implantation of the huChon spheroids, the mice did
not show any signs of inflammatory reactions. All wounds
caused by the implantation procedure healed well. From
the day of implantation to sacrifice after 31 ± 1 days, body
weights increased in all animals. The mean body weight of
all mice was 21.9 ± 1.1 g at the day of spheroid implant-
ation and 24.7 ± 1.2 g at the day of sacrifice. None of the
animals showed weight loss of more than 20 %, health
score > 0, or abnormalities with routine palpation during
husbandry (Fig. 1; method I, II). Thus, all 40 mice were
sacrificed 31 ± 1 days after implantation and not earlier.
None of the mice showed any abnormality with routine
palpation and macroscopic inspection on the day of sacri-
fice (Fig. 1; III, IV). The macroscopic appearance of organs
was normal.
ATMP was retrievable at one month post implantation
but partially fragmented
After isolation and spreading of the back skin, huChon
spheroids were macroscopically visible at the implant-
ation site in 39 out of 40 (39/40) mice (Fig. 1; V). In one
mouse (MB1) the exact location of the spheroid could not
clearly be identified by eye. This mouse was considered as
potentially positive for biodistribution. Thus, complete
qPCR analyses of the 10-mm and 20-mm rings and the se-
lected organs were performed.
Overall, the huChon spheroids were weakly visible at
the implantation site and appeared macroscopically with a
bright yellow color (Fig. 4a, d). Thus, they could hardly be
discriminated from the surrounding mouse tissue. In con-
trast, inverse-microscopy allowed for better discrimination
(Fig. 4b, e). In 5/39 mice the spheroids were found to be
fragmented (Fig. 4e).
No histological signs of biodistribution
To observe possible histological signs for local migration
of human chondrocytes out of the huChon spheroid into
the surrounding skin area in situ, IHC of HLA-ABC was
performed to detect the presence of human cells (Fig. 1;
VIa). From the 40 analyzed 4-mm discs containing the
huChon spheroid, 2,556 sections were stained and assessed
blindly. The positive HLA-ABC staining (Fig. 4g) and the
negative IgG2a isotype-control (Fig. 4h) of huChon spher-
oid sections demonstrated the specificity of the staining.
The huChon spheroids within the serial sections were
shaped normally or fragmented (Fig. 4c, f ). In both cases
we did not observe any signs of active cell migration such
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drocytes from the huChon spheroids. An indirect indica-
tion for human cell migration such as local inflammation
was also not observed. The fragmentation of the huChon
spheroid in 5/39 mice (Fig. 4e, f ) was caused either by
mechanical stress during subcutaneous implantation, or
the HLA-positive “cell islets” outside the spheroid result
from a deformed but intact spheroid as demonstrated by
3D reconstruction of serial sections (Fig. 4i–k). Because
no indications of local migration were observed, detection
of human cells by IHC in organs (Fig. 1, VIb) was not
mandatory according the study plan.
However, as a limitation of the fixed safety testing strat-
egy, only 23/40 of the 4-mm skin discs could be included
for evaluation of biodistribution by IHC. The remaining
17 samples were excluded due to the suspicion of tech-
nical uncertainties. This included slipping of the spheroids
from the inner 4-mm disc into the 10-mm ring and loss of
spheroids during isolation throughout the punching of the
inner 4-mm disc because of the very soft consistency of
this test item and its loose association with the mouse
fascia. However, all 40 mice were evaluable in the qPCR
analysis, performed in parallel to the IHC analyses.
qPCR revealed no indications for biodistribution into skin
or organs
Using the validated Triplex qPCR, the 10-mm skin ring
was examined first (Fig. 1, VIIa). A total of 760 qPCR reac-
tions were performed. According to the determined detec-
tion limit of ≥ 5 cells, 33/40 areas were negative and 7/40
were positive for human DNA. Two out of these seven
samples were also positive for male DNA probably through
contamination with human DNA by male staff, detected
by the implemented gender control. According to the bio-
distribution flow chart these seven samples were classified
as potentially positive for local migration and subsequently
the 20-mm ring was analyzed by qPCR (Fig. 1; VIIb). This
included a total of 386 qPCR assays. In none of these sam-
ples human DNA was detected, suggesting there was no
migration. Thus, in our opinion, the positive 10-mm rings
were most likely caused by slipping of the soft spheroids or
spheroid parts during punching from 4-mm disc into the
adjacent area.
The qPCR analyses that were performed met the re-
quirements established in the biodistribution flow chart.
However, due to remaining uncertainties for the 17 ani-
mals, which were not evaluable by IHC (see above), we
decided to perform additional qPCRs from a random
sample of 7 out of these 17 animals (corresponding to
40/102 organs, see Additional file 1: Figure S1).
For the determination and evaluation of this random
sample we followed the procedure as described in ISO
2859-I, Tables I and II. In brief, using an acceptance
quality limit of 0.1 (error rate in % according to a 5 %risk for assuming migration even if it does not occur
[=alpha error]) and normal inspection, 32 organs would
need to be investigated. None of these organs would be
allowed to test positive, otherwise the null hypothesis
would be rejected.
Analyzing the 40 organs from these 7 mice by qPCR
we found no positive result, thus the null hypothesis was
acceptable. According to the operational characteristics
of this statistical test design, a limiting quality value of 4
% (5.5 %, 7.2 %) was obtained corresponding to an error
rate of 80 % power (90 %, 95 %) to detect migration even
if it does not occur (=beta error).
In summary, there was no suspicion of biodistribution
of spheroid-derived human chondrocytes using qPCR.
Final evaluation of the biodistribution study
Overall, examining biodistribution by the applied com-
bined methods ensured high sensitivity and specificity for
testing a human ATMP in immunodeficient NSG mice.
Because there was no evidence of local migration into
the adjacent skin and for biodistribution into the tested
organs, the subsequent tumorigenicity study did not need
to be performed with particular attention to any special
tissues or organs.
Tumorigenicity study
The flow chart in Fig. 2 summarizes both the prospect-
ively planned tumorigenicity study as well as the ob-
tained results.
No mice in the huChon spheroid group developed a
tumor at the implantation site
After implantation of the huChon spheroids, the mice
did not show any signs of inflammatory reactions and all
wounds healed well. None of the animals showed a
health score > 0, weight loss (body weights increased by
6.6 ± 1.8 g over time, corresponding to 30.5 ± 8.6 % in-
crease of the body weight (Fig. 5a) or abnormalities with
routine palpation (Fig. 2; method I, II). Thus, all mice
were sacrificed 180 ± 5 days post implantation. A tumor
was not found by routine palpation or macroscopic in-
spection in any mice on the day of sacrifice (Fig. 2; III,
IV). In contrast, all mice of the Caco-2 positive reference
group were required to be sacrificed just 22 or 23 days
post implantation (Fig. 5b) according to the defined
break-off criteria. The health score of these mice was 2 or
3. All mice of this group developed a tumor at the im-
plantation site, mostly combined with an open wound.
The growing tumors exhibited a highly catabolic metabol-
ism because mouse body weights decreased from day 14
onwards (Fig. 5a). No other tumors were detected in these
mice.
Unexpectedly, all animals of the NIH/3T3 group de-
veloped tumors at the implantation site and had a health
Fig. 5 (See legend on next page.)
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Fig. 5 Tumorigenicity study: Comparison of the huChon spheroid group with the reference groups. Changes of mouse body weight over time
normalized to the body weight at implantation of the test item (a). Note: ± 2 SD in (k) covers approx. 95 % of all data in the sample. Dis.: Time
point of dissection. Percentage of living animals of the three study groups to show the fraction of mice living for a certain amount of time
after implantation (b). Animals of the Caco-2 and NHI/3T3 group were sacrificed just before the planned study time according to the defined
break-off criteria. Macroscopic view at the prepared implantation site of one representative mouse of each group before (c–e) and after (f–h)
dissection. No tumor but the implanted huChon spheroid was located at the implantation site (f, arrow), whereas tumors were observed
in the NIH/3T3 (g) and Caco-2 groups (h). Representative anti-HLA-ABC staining of a section through the implantation site of each group (i–k).
The huChon spheroids and the tumors derived from human Caco-2 but as expected not from murine NIH/3T3 cells showed a positive HLA-ABC
staining. Bars indicate 200 μm
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teria 6/8 mice had to be sacrificed between day 84 and
167 post implantation. Only two mice could be kept
alive for 180 ± 5 days. After sacrifice, other tumors were
not detected by palpation.
Karyotyping of NIH/3T3 cells
Karyotyping was performed of the NIH/3T3 cell line at
different cultivation times to authenticate it and to clar-
ify why these murine cells formed tumors in NSG mice.
Analyzing 25 metaphase cells by GTG-banding and SKY
for each probe, we could confirm the predominant oc-
currence of the hypertriploid karyotype in NIH/3T3. In
the first analysis of the recultivated cells after arrival, we
were able to identify the novel recurrent nonreciprocal
unbalanced translocations t(1;15)(C2;?) and t(7;4)(?;?).
Additionally, specific structural chromosomal aberra-
tions such as terminal deletions del(4)(B2), del(7)(F1),
and del(12)(C2) were detected as single events. Most of
these chromosomal aberrations were confirmed at pas-
sage 14, the time of implantation. Recurring terminal
deletion del(4)(B2) was found in 57 % of the analyzed
metaphases. The incidence of this deletion increased up
to 100 % in explanted tumors of the NSG mouse. The ter-
minal deletion del(7)(F1) additionally occurred in 83 % of
the analyzed metaphases of the tumors. In particular, these
two deletions might have contributed to tumor formation.
Thus, the accumulation of chromosomal deletions during
cultivation of NIH/3T3 cells and incubation in NSG mice
provides evidence for a tumorigenic geno- and phenotype
of this cell line.
Dissection revealed possible tumor-related changes in
tissues of the huChon spheroid group
The implanted huChon spheroids were detected at the
implantation site but no tumor formation or other ab-
normality was observed (Fig. 5c, f, i).
During mouse dissection, organs or tissues of 5/40
mice showed possible tumor-related abnormalities (Fig. 2,
step V; Fig. 6) that needed further histopathological ana-
lysis by HE and HLA-ABC staining (Fig. 2, steps VI,
VIII): In the liver of mouse 1 of the tumorigenicity study
(MT1), in the intestine of MT2, in the abdominal skin ofMT3 and MT4 and in the right pulmonary lobe of MT5.
Two of five of these tumor-suspicious organs or tissue
sites were subsequently classified by histopathology as
tumors. In the liver of MT1, the suspicious area showed
histological signs of a hepatoma with small necroses
whereas the suspicious area in the colon of MT2 was
classified as a small neurinoma, both benign tumors.
However, both tumors were HLA-ABC negative (Fig. 6)
suggesting that they were spontaneous murine rather than
human chondrocyte-derived tumors. The suspicious areas
in the skin of animals MT3 and MT4 turned out to be hair
retention cysts, not tumors. The observed abnormality in
the lung of MT5 was assessed as a microfocal, benign mal-
formation. However, all five conspicuous mice got huChon
spheroids from five different donors. Therefore, a link be-
tween donors and tumorigenesis did not exist.
In the Caco-2 and NIH/3T3 groups, apart from the tu-
mors at the implantation site (Fig. 5d, e, g, and h), no
other tumors were observed during mouse dissection.
The average volume of the tumor at time of sacrifice
was 1.25 ± 0.56 cm3 in the Caco-2 and 2.01 ± 1.64 cm3 in
the NIH/3T3 group. The tumors derived from NIH/3T3
cells grew significantly slower compared to Caco-2-derived
tumors. Due to cachexia, in the Caco-2 group the absolute
organ weights were significantly lower compared to that
of the other groups whereas the relative organ weights
were mostly higher due to more rapid decrease of the
body weight compared to the organ weight (Additional
file 2: Figure S2). The absolute and relative organ weight
of the mice with tumor-suspicious organs or tissues did
not differ from that of other mice. Thus, examination of
organ or tissue weights (Fig. 2, method VII) was not useful
to detect tumor growth outside spheroid implantation
site.
Final evaluation of the tumorigenicity study
Overall, examining tumorigenicity by combining methods
ensures safe testing of human ATMPs in immunodeficient
NSG mice and resulted in cost savings. However, the
weight measurement of organs was not sensitive enough to
detect small tumors. There were no indications of increased
prevalence of tumors after implantation of huChon spher-
oids in the applied NSG mouse model.
Fig. 6 Tumorigenicity study: HE and HLA-ABC staining of serial
sections of abnormal organs or tissues from five mice of the
huChon group. MT1: liver, hepatoma (benign); MT2: colon, small
neurinoma (benign); MT3 and MT4: abdominal skin, hair retention cysts
(no tumors); MT5: pulmonary lobe, microfocal, benign malformation
(no tumor). Thus, only the suspicious areas of mice MT1 and MT2 were
classified histopathologically as tumors. However, these tissues were
HLA-ABC negative suggesting that they are spontaneous murine rather
than human tumors. IHC controls: Sections of human skin stained with
the IgG2a isotype control (left) and with the anti-HLA-ABC (right)
antibodies served as staining controls. Bars indicate 200 μm
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The aims of the present study were first to design a strategy
to evaluate biodistribution and tumorigenicity of ATMPs
without previous cell manipulation, implementing con-
siderations and demands of the regulatory authority, and
secondly, to apply this approach in the assessment of safety
issues of the human cartilage ATMP co.don chondro-
sphere®. These non-clinical studies are necessary for cen-
tral market authorization in the European Union.
To the best of our knowledge, this is the first report on
a comprehensive GLP safety and efficacy study on a hu-
man ATMP for cartilage repair. Until now, only limitednon-clinical data have been published regarding safety of
cell-based medicinal products [22]. Our study delivers
relevant non-clinical safety data for the investigated TEP.
Even more important, it provides an example of a com-
prehensive and validated testing strategy which is in
agreement with EMA and FDA guidelines for non-clinical
safety testing of TEPs, sCTMPs and combined ATMPs
under GLP.
Xenogeneic graft placement of human ATMPs requires
an immunodeficient animal model. The NSG mouse ex-
presses one of the most pronounced immunodeficient
phenotypes [23] and represents the most widely used
model available for studying human xenografts in mice
in vivo [24]. Moreover, the induction of tumors after im-
plantation of various cancer cell lines was higher in NSG
compared to other immunodeficient mouse strains such
as SCID, NOD-SCID or NSB [25,26]. In agreement with
the PEI, we favored a heterotopic variant for spheroid im-
plantation because of the murine knee anatomy. Although
intra-articular injection of fibroblasts into the knee joint is
feasible in mice [27] this invasive procedure may destroy
regular structures in the knee joint. In contrast, subcuta-
neous implantation is easier to perform, is non-invasive,
and offers the advantage that several test items may be ap-
plied in one mouse [28].
To test biodistribution, xenogeneic cells in mouse or-
gans were quantified by analyzing species-specific, non-
coding DNA sequences using qPCR [7]. In the present
study, sensitivity using the Plexor® HY system was 5 cells
per 50 mg mouse tissue which corresponded to 0.96 cm2
back skin. Thus, five cells could be detected safely within
0.66 cm2, the area of the 10-mm skin ring. Based on our
results for macro- and microscopic evaluation and qPCR,
there was no biomolecular evidence of biodistribution of
human chondrocytes or huChon spheroids away from the
implantation site. Generally, chondrocytes are able to
move in 2D and 3D environments in vitro with a speed of
1-15 μm/h [29,30]. Although in-vivo migration is more
complex, based on these data, migration up to 11.2 mm
distant from the spheroid and thus into the 20-mm skin
ring might be possible within one month. However, this
was not evident. The few HLA-ABC positive 10-mm skin
rings were most likely caused by partial deformation or
fragmentation of the soft spheroid and were judged as
false positives. Correspondingly, the data from an assess-
ment report for approval of “Matrix applied characterized
autologous cultured chondrocytes” (MACI®, Genzyme/
Sanofi) to the EMA revealed no biodistribution from the
orthotopic implanted cells into popliteal and ileofemoral
lymph nodes in a preclinical horse model (Study GENZ
09–4417, [13]).
A limitation of the prospectively defined biodistribu-
tion testing strategy is that only 23/40 huChon spheroids
could be recovered unequivocally by IHC. The loss of
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to the soft consistency of the analyzed ATMP.
To overcome this detection bias, an additional random
sample of the organs of 7 mice out of the 17 mice which
were immunohistochemically not evaluable was analyzed
more extensively by qPCR (Additional file 3: Figure S3).
In this random sample, no biodistribution was observed.
In future non-clinical studies regarding testing of
similarly small and soft test items, the processing of the
samples for IHC should be carefully adjusted in order to
maximize the number of animals evaluable by IHC.
In the tumorigenicity study, the huChon spheroids but
no tumors and metastases were detected at the implant-
ation site of all mice after six months. Because the previ-
ous biodistribution study yielded no signs of migration
from the huChon spheroids one month after implantation,
tumor formation outside the implantation site was not
anticipated. However, in two mice HLA-ABC-negative
benign tumors were detected, indicating that these tumors
were of murine origin and occurred spontaneously with-
out relation to the huChon implantation. Data on the inci-
dence of spontaneous tumors are not available for NSG
mice but are available for other mouse strains [31]. In 17/
32 inbred mouse strains, the liver was one of the organs
which was often affected [31]. As an example, in immuno-
deficient C.B–17;ICR-Prkdcscid (SCID) mice, spontaneous
liver tumors were observed in 0–14 % of the animals.
Thus, the liver tumor incidence of 2.6 % in our study was
within this range. Spontaneous intestinal tumors appeared
in 14/32 of the inbred mouse strains [31]. In our study,
the incidence of such tumors was 2.6 % and thus compar-
able to that in the literature [32]. Moreover, the formation
of spontaneous hepatomas, observed once in our study,
increased during the lifetime of inbred mouse strains and
was nearly 100 % in 120-week old animals [33].
In the tumorigenicity study we included two reference
cell lines. As a positive reference which would certainly
induce tumors after subcutaneous implantation into the
neck, we would have preferred chondrocyte-derived ma-
lignant cells [34], but the murine OUMS-27 chondrosar-
coma [35] proliferated too slowly and did not form
spheroids in vitro according to the co.don protocol.
After expert advice from the PEI, the German respon-
sible authority, we used Caco-2 cells as a positive refer-
ence, as they proliferate faster and form spheroids. For
the second reference, NIH/3T3 cells planned as negative
reference, tumor growth in mice was unexpected when
formulating the study plan. These cells did not develop
tumors in SCID mice in an internal pilot study. It is
likely that NSG mice might be more sensitive for tumor
formation. However, the accumulated chromosomal
anomalies of the NIH/3T3 cells used in this study were
considered to be the predominant cause of NIH/3T3-
related tumor growth in our in-vivo model. Thus, theNIH/3T3 cell line is not a suitable negative reference con-
trol for testing tumorigenicity of ATMPs. In conclusion,
cell lines with an abnormal karyotype bear the risk of
tumor formation, particularly in immunocompromised
animal models. Freshly isolated primary fibroblasts would
provide an ideal but not feasible or reproducible cellular
source as a negative reference.
Conclusions
In summary, we developed a strategy to study the safety
of human ATMPs under GLP conditions. The analysis
of the chondrocyte-based TEP co.don chondrosphere®
revealed no risk for biodistribution. The subsequent
tumorigenicity study also revealed no indications of in-
creased tumor frequency in the applied NSG mouse model.
The step-wise, sequential strategy presented here lowers
personnel and material costs of expensive safety testing.
This strategy might serve as a good basis for non-clinical
safety studies of other solid cell-based ATMPs in a mouse
model, including TEPs, sCTMPs and combined ATMPs.Additional files
Additional file 1: Figure S1. Pilot batch for the development of the
immunohistochemical staining procedure of huChon spheroids within
mouse skin. Blocking of endogenous peroxidase (+) showed a
significantly reduced background compared to non-blocked sections
(A) in the area of epidermis/hair follicles as well as in the deeper
layer around the implanted spheroid (arrow head). Besides blocking
of endogenous peroxidase, the sections were blocked with different
concentrations of human serum (HS) before incubation with the primary
anti-human antibody (B). 1 % HS was the best. The non-specific background
(arrows) increased with HS concentration.
Additional file 2: Figure S2. Organ weights of mice in the tumorigenicity
study. Absolute organ weights (A) of the three groups and relative organ
weights (B) as a percentage of body weight (BW). Error Bar Chart (mean ± 2
SD) of tumor size by group. Note: ± 2 SD covers approx. 95 % of all data in
the sample.
Additional file 3: Figure S3. Biodistribution study: Flow chart of the
4-mm skin discs that could not be evaluated by IHC due to technical/
product specific reasons. The steps with continuous lines were performed
according to the study plan. The dashed lines indicate the organ analysis
by qPCR, performed additionally to the study plan on seven random
samples (including mouse MB1). This was performed to further increase
the level of security. The Roman numerals have been adopted from the
biodistribution flow chart (Fig. 1). aA total of 102 organs were isolated
from all 17 mice. From these, a sample of 40 organs was analyzed by
qPCR (see section of qPCR results). The 40 analyzed organs are calculated
as follows: 7 mice × 5 organs (lungs, liver, left and right kidney, spleen) +
local lymph nodes of 5 mice. Due to the very small lymph nodes of the
NSG mouse [31] they could only be isolated from 5 out of 7 mice.Abbreviations
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